Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer ...

Mounjaro will soon be available on the NHS across the UK but it's important patients avoid the dangerous 'golden dose' trend ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

(Reuters) -Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can ...

(Reuters) -A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market ...